CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, MS RCE, P. O. Box 1450, Alexandria, Virginia 22313-1450, on May 20, 2004.

Jeanne Amour

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Kenneth CHIEN

Serial No.: 09/830,779

Filing Date: November 30, 2001

For: A METHOD FOR INHIBITION OF

PHOSPHOLAMBAN ACTIVITY FOR THE TREATMENT OF CARDIAC DISEASE AND HEART FAILURE Examiner: P.A. Duffy

Group Art Unit: 1645

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

	This In	formation Disclosure Statement is submitted:
	With	the application; accordingly, no fee or separate requirements are required.
\boxtimes	Befor	re the mailing of a first Office Action after the filing of a Request for Continued
	Exan	nination under § 1.114. However, if applicable, a certification under 37 C.F.R. §
	1.97	(e)(1) has been provided.
	With	in three months of the application filing date or before mailing of a first Office
	Actio	on on the merits; accordingly, no fee or separate requirements are required.
	Howe	ever, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
	After	receipt of a first Office Action on the merits but before mailing of a final Office
	Actio	on or Notice of Allowance.
		A fee is required. A check in the amount of is enclosed.
		A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached
		to this submission in duplicate.
		A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee
		is believed to be due.
	After	mailing of a final Office Action or Notice of Allowance, but before payment of the
	issue	fee.
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the
		amount of is enclosed.
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal
		form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petitions for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing (docketno). However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Date:

Respectfully submitted,

Gregory P. Einhorn Reg. No. 38,440

Morrison & Foerster LLP 3811 Valley Centre Drive, Suite 500 San Diego CA 92130 direct dial 858 720 5133 fax 858 720 5125

Form PTO-1449					Docket Number (220002066200)		Application Number (09/830,779)		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION					Applicant (Kenneth CHIEN)				
	(U	se several sheets if	necessary)		Filing Date (November 30, 2001) Group Art Unit (1645)				
,					Mailing Date May 20, 2	004			
	,		U.S. PA	TEN'	Γ DOCUMENTS		=		
Examiner Initials	Ref. No.	Date	Document No.		Name	Class	Subclass	_	Date If opriate
			FOREIGN I	PATI	ENT DOCUMEN	TS			·N
Examiner Initials	Ref. No.	Date	Document No.	Country		Class	Subclass	Trans YES	lation NO
	1	24 June 1999	WO99/30696	WII	PO		(
			OTHE	R DO	OCUMENTS	(includi	ng author, title, Da	te, Pertinent	Pages, Etc.)
Examiner Initials	Ref. No.	Title							
	2	Koss, K.L., et al "Phospholamban: A Prominent Regulator of Myocardial Contractility", Vol. 79, No. 6, 1 December 1996, pgs. 1059-1063							
	3.	Dillmann W.H., "Influences of Increased Expression of the Ca2+ ATPase of the Sarcoplasmic Reticulum by a Transgenic Approach on Cardiac Contractility", Annals of the New York Academy of Science, 16 September 1998, pgs. 43-48							
,	4.	He, Huaping, et al., "Influence of an Antisense Phospholamban Transcribed by an Adenoviral Vector on Ca2+ ATPase In Cardiac Myocytes", Journal of Molecular and Cellular Cardiology, Vol. 29, No. 6, 1997, p. 106							
	5.	He Huaping et al.; "Effects of mutant and antisense RNA of Phospholamban on SR Ca2+-ATPase Activity and Cardiac Myocyte Contractility", Vol. 100, No. 9, 31 August 1999, pps. 974-980							
	6. Toyofuku, Toshihiko, "Amino Acids Glu2 to Ile18 in the Cytoplasmic Domain of Phospholamban Are Essential for Functional Association with the Ca2+-ATPase of Sarcoplasmic Reticulum", Vol. 269, No. 4, 28 January 1994, pps. 3088-3094								
EXAMIN	EXAMINER:				DATE CONSI	DERED:			
			idered, whether or not the				line through the c	itation if no	ot in

PATENT COOPERATION TREA.

From the INTERNATIONAL SEARCHING AUTHORITY

To: McCLAIN, James, W. Attn. MUSICK, ELEANOR M. Brown, Martin, Haller & McClain 1660 Union Street San Diego, CA 92101-2926

PCT

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT OR THE DECLARATION

Applicant's or agent's file reference
6627-PC9025
International application No.
PCT/US 99/25692
Applicant
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA et al.

1. X	The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.
l	Filing of amendments and statement under Article 19:
	The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):
	When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.
	Where? Directly to the International Bureau of WIPO
	34, chemin des Colombettes
	1211 Geneva 20, Switzerland
	Fascimile No.: (41–22) 740.14.35
	1 ascinille 140 (41–22) 7 40.14.05
	For more detailed instructions, see the notes on the accompanying sheet.
2.	The applicant is hereby notified that no International Search Report will be established and that the declaration under
_	Article 17(2)(a) to that effect is transmitted herewith.
3.	With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:
	the protest together with the decision thereon has been transmitted to the International Bureau together with the
	applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.
	-
	no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.
	, , , , , , , , , , , , , , , , , , , ,
4. Fu	rther action(s): The applicant is reminded of the following:
٥.	
Sh	ortly after 18 months from the priority date, the international application will be published by the International Bureau.
11	the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the
p	nority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the
c	ompletion of the technical preparations for international publication.
\A <i>F</i> :4	his 40 manths from the existing data a demand facility of a large of the facility of the facil
VVII	thin 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant
VV	rishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).
Wit	hin 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase
b	efore all designated Offices which have not been elected in the demand or in a later election within 19 months from the
n	fighty date or could not be elected because they are not bound by Chanter II
р	riority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority

European Patent Office, P.B. 5818 Patentiaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Authorized officer

Nina Vercio

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been fis filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

- [Where originally there were 48 claims and after amendment of some claims there are 51]:
 Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added.
- [Where originally there were 15 claims and after amendment of all claims there are 11]: "Claims 1 to 15 replaced by amended claims 1 to 11."
- [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims];
 - "Claims 1 to 6 and 14 unchanged, claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or "Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
- [Where various kinds of amendments are made]:
 Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claims 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added.

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international appplication is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guida

PATENT COOPERATION TREA. .

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER see Notification o (Form PCT/ISA/2)	of Transmittal of International Search Report 20) as well as, where applicable, item 5 below.
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/US 99/25692	02/11/1999	02/11/1998
Applicant	4	I.
THE REGENTS OF THE UNIVER	SITY OF CALIFORNIA et al.	
This International Search Report has been according to Article 18. A copy is being tra	n prepared by this International Searching Auth ansmitted to the International Bureau.	nority and is transmitted to the applicant
This International Search Report consists It is also accompanied by	of a total of sheets. a copy of each prior art document cited in this	герогі.
Basis of the report		-
 With regard to the language, the language in which it was filed, unit 	international search was carried out on the bas less otherwise indicated under this item.	is of the international application in the
the international search w Authority (Rule 23.1(b)).	ras carried out on the basis of a translation of th	ne international application furnished to this
•	d/or amino acid sequence disclosed in the int	ternational application, the international search
	onal application in written form.	
filed together with the inte	mational application in computer readable form).
furnished subsequently to	this Authority in written form.	•
furnished subsequently to	this Authority in computer readble form.	
, the statement that the sub international application as	osequently furnished written sequence listing do s filed has been furnished.	ses not go beyond the disclosure in the
the statement that the info furnished	rmation recorded in computer readable form is	identical to the written sequence listing has been
2. X Certain claims were four	nd unsearchable (See Box I).	
3. Unity of Invention is lack	· · · ·	
	3119 (550 257 11).	•
4. With regard to the titte,		
the text is approved as sub	bmitted by the applicant.	
	ned by this Authority to read as follows:	
·		•
5. With regard to the abstract,		
the text is approved as sub the text has been establish within one month from the	omitted by the applicant. ned, according to Rule 38.2(b), by this Authority date of mailing of this international search repo	as it appears in Box III. The applicant may, ort, submit comments to this Authority.
6. The figure of the drawings to be publis		
as suggested by the applic		None of the figures.
because the applicant faile		[··]
because this figure better c	•	

INT RNATIONAL SEARCH REPORT

sternational Application No

PCT/US 99/25692 A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K38/17 A61K A61K47/48 A61P9/04 C07K17/00 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K C07K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No. Citation of document, with indication, where appropriate, of the relevant passages Category ^e 1-5. X KOSS K L ET AL: "PHOSPHOLAMBAN: A 12 - 17PROMINENT REGULATOR OF MYOCARDIAL CONTRACTILITY" CIRCULATION RESEARCH, vol. 79, no. 6, 1 December 1996 (1996-12-01), pages 1059-1063, XP002053754 ISSN: 0009-7330 the whole document 1-5,DILLMANN W H: "Influences of increased X expression of the Ca2+ ATPase of the 12 - 17sarcoplasmic reticulum by a transgenic approach on cardiac contractility.' ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, (1998 SEP 16) 853 43-8., XP000914521 page 46, line 47 -page 47, line 16 Patent family members are listed in annex. Further documents are listed in the continuation of box C. Special categories of cited documents : *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention filing date cannot be considered novel or cannot be considered to document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-*O* document referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled other means document published prior to the international filing date but "&" document member of the same patent family later than the priority date claimed Date of mailing of the international search report Date of the actual completion of the international search 20/06/2000 5 June 2000

Authorized officer

C+ a + m

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel 7 (31...70) 340...2040 Tv (31.651.eng.nl

INT NATIONAL SEARCH REPORT

ternational Application No PCT/US 99/25692

		C1/U3 99/23092
C.(Continu Category *	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HE HUAPING ET AL: "Influence of an antisense phospholamban transcribed by an adenoviral vector on Ca-2+ ATPase in cardiac myocytes." JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, vol. 29, no. 6, 1997, page A181 XP000907558 ISSN: 0022-2828 the whole document	1-5, 12-17
X	WO 97 37224 A (MEDICAL RES COUNCIL; BARFORD DAVID (GB); COHEN PHILIP (GB); COHEN) 9 October 1997 (1997-10-09) page 32, line 1 - line 7	1,12,13
X	FR 2 753 722 A (SMITHKLINE BEECHAM LAB) 27 March 1998 (1998-03-27) the whole document	1,12,13
A	TOYOFUKU T ET AL: "Amino acids Glu2 to Ile18 in the cytoplasmic domain of phospholamban are essential for functional association with the Ca2+-ATPase of sarcoplasmic reticulum" THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 4, 28 January 1994 (1994-01-28), pages 3088-3094, XP002139384 cited in the application the whole document	1-5, 12-17
A	US 5 652 122 A (PABO CARL ET AL) 29 July 1997 (1997-07-29) the whole document	6-11
Ρ,Χ	MINAMISAWA SUSUMU ET AL: "Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy." CELL , vol. 99, no. 3, 29 October 1999 (1999-10-29), pages 313-322, XP002139385 ISSN: 0092-8674 the whole document	1-5, 12-17
	-/	
, [

INTERNATIONAL SEARCH REPORT

Aernational Application No
1 PCT/IIS 99/25692

		PCT/US 99	/25692
C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.
P,X	HE HUAPING ET AL: "Effects of mutant and antisense RNA of phospholamban on SR Ca2+-ATPase activity and cardiac myocyte contractility." CIRCULATION, vol. 100, no. 9, 31 August 1999 (1999-08-31), pages 974-980, XP000907563 ISSN: 0009-7322 the whole document		1-17
Ρ,Χ	WO 99 30696 A (HAIKALA HEIMO ;OVASKA MARTTI (FI); KAHEINEN PETRI (FI); KAIVOLA JU) 24 June 1999 (1999-06-24) the whole document		1,12,13
			*
	,		v.
	· .		. ,
			·
	,		· X-
			• •
		•	

INTERNATIONAL SEARCH REPORT

International application No. PCT/US 99/25692

Box I	Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)
This Inte	emational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. χ	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
	Although claims $1-5$, $12-17$ are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.	Claims Nos.:
ري ۳	because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)
This Inte	emational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
	of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
	restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	on Protest The additional search fees were accompanied by the applicant's protest.
	No protest accompanied the payment of additional search fees.

INTRNATIONAL SEARCH REPORT

...rormation on patent family members

ternational Application No PCT/US 99/25692

			5.00			
-	atent document d in search repor	rt	Publication date		Patent family member(s)	Publication date
WO	9737224	Α	09-10-1997	AU	2172597 A	22-10-1997
				CA	2250826 A	09-10-1997
				EP	0891551 A	20-01-1999
FR	2753722	A	27-03-1998	MO	9813518 A	02-04-1998
US	5652122	Α	29-07-1997	US	5674980 A	07-10-1997
		•		US	5804604 A	08-09-1998
				US	5670617 A	23-09-1997
			•	US	5747641 A	05-05-1998
				AT	142266 T	15-09-1996
				AU	658818 B	04-05-1995
				AU	7182991 A	24-07-1991
				CA	2071214 A	22-06-1991
			,	DE	69028412 D	10-10-1996
				DE	69028412 T	27-03-1997
				DK	506884 T	04-11-1996
				EP	0506884 A	07-10-1992
				ES	2091916 T	16-11-1996
				GR	3021474 T	31-01-1997
				WO	9109958 A	11-07-1991
				AT	173016 T	15-11-1998
				AU	667244 B	14-03-1996
				AU	5083293 A	15-03-1994
				CA	2135642 A	03-03-1994
				DE	69321962 D	10-12-1998
				DE	69321962 T	01-07-1999
				DE	656950 T	14-03-1996
				EP	0656950 A	14-06-1995
				EP	0903408 A	24-03-1999
		4		ES.	2123062 T	01-01-1999
				FΙ	945248 A	05-01-1995
			•	JP	2869396 B	10-03-1999
				ĴΡ	10033186 A	10-02-1998
			•	JP	2702285 B	21-01-1998
				ĴΡ	7503617 T	20-04-1995
				KR	153027 B	15-10-1998
				NO -	944273 A	17-02-1995
				NZ	255831 A	24-04-1997
				WO	9404686 A	03-03-1994
 WO	9930696	Α	24-06-1999	 AU	1565599 A	05-07-1999
				ÜS	5968959 A	19-10-1999